INNATE PHARMA SP.ADR/1 (IDDA) — Strategic Asset Allocation Index
INNATE PHARMA SP.ADR/1 (IDDA) has a Strategic Asset Allocation Index of 202.0% as of June 2025. Strategic assets (PP&E of €- plus long-term investments of €10.39 Million) total €10.39 Million, measured against net assets of €5.14 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See IDDA net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
INNATE PHARMA SP.ADR/1 Strategic Asset Allocation Index (2021–2024)
This chart shows how INNATE PHARMA SP.ADR/1's Strategic Asset Allocation Index has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the index stands at 202.0%, representing strategic assets of €10.39 Million against net assets of €5.14 Million EUR. For live market cap and overall valuation, see INNATE PHARMA SP.ADR/1 market cap and net worth.
Annual Strategic Asset Allocation Index for INNATE PHARMA SP.ADR/1 (2021–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for INNATE PHARMA SP.ADR/1 from 2021 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See INNATE PHARMA SP.ADR/1 shareholders equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 116.4% | €10.28 Million | €- | €10.28 Million | €8.83 Million | ▲ +97.5 pp |
| 2023 | 18.9% | €9.80 Million | €- | €9.80 Million | €51.90 Million | ▼ -46.0 pp |
| 2022 | 64.9% | €35.12 Million | €- | €35.12 Million | €54.15 Million | ▲ +27.7 pp |
| 2021 | 37.1% | €39.88 Million | €- | €39.88 Million | €107.44 Million | — |